Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas

Prognostic Importance of Quantitative Magnetic Resonance Imaging for Evaluation of Pancreatic Steatosis in Patients With Pancreatic Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02682394

Enrollment

Registered

2016-02-15

Start date

2015-09-30

Completion date

2017-10-31

Last updated

2016-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of Pancreas

Keywords

Cancer of pancreas, steatosis, MRI

Brief summary

Prognostic Importance of Quantitative Magnetic Resonance Imaging for Evaluation of Pancreatic Steatosis in Patients with Pancreatic Cancer

Detailed description

1. Finding patients with pancreatic cancer (in all stages), before any treatment. 2. Non invasively quantify fatty infiltration of pancreas using, MRI DIXON Scan in pancreatic cancer patient relatively to liver. 3. Measuring cell-free blood DNA in those patients for evaluating the aggressiveness of the disease. 4. Quantify the prognostic significance of pancreatic steatosis in comparison with clinical and pathological prognostic indexes used today.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients diagnosed with any pancreatic cancer, in any stage, before treatment. * \>18 y.o

Exclusion criteria

* claustrophobia * GFR\<30 * patients with non mri compatible devices (e.g. orthopaedic external fixation system) * After chemotherapy treatment or surgical procedure

Design outcomes

Primary

Measure	Time frame	Description
Percentage of fat in pancreas measured in the head, body and tail excluding the lesion area.	at 24 hours before chemotherapy starting	measuring Pancreatic Steatosis in patients with pancreatic cancer using MRI DIXON scan, at 24 hours before chemotherapy starting.
Blood levels of free DNA	The blood sample taken 15 minutes prior to MRI study, at time of IV access.	Correlation of free DNA level and metastatic spread.

Countries

Israel

Contacts

Primary ContactVladimir Borodetsky, MD

zivova1982@gmail.com+972547428882

Backup ContactIrena Lazerev, MD

irinalaz@clalit.org.il+972526226458

Outcome results